ClinicalTrials.gov
public full text
Public Domain
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
The study is being conducted to explore the safety and effectiveness of a new chemical entity, BGC20-1531, in subjects with a history of migraine. In this study subjects will treat a total of three migraine attacks with two different doses of BGC20-1531 and placebo, with at least one week wash out period between doses.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety of Oral NBP Soft Capsules for the Prevention of Episode Migraine Attacks in Adult Migraine Patients#918499
- Investigation of the Effect of Cold Application in Migraine#829137
- Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine#993711
- Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches#825038
- Ginger Capsules for the Acute Treatment of Migraine Attacks#1100634
Record · ID 1384702
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive